The present invention relates to inhibitors of 11-β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
[EN] PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS POUR PRÉPARER DU ZANUBRUTINIB ET SES INTERMÉDIAIRES
申请人:TEVA PHARMACEUTICALS INT GMBH
公开号:WO2022125862A1
公开(公告)日:2022-06-16
The present disclosure provides new procedures and intermediates for the preparation of Zanubrutinib.
本公开提供了制备Zanubrutinib的新程序和中间体。
Direct, Selective α-Aryloxyalkyl Radical Cyanation and Allylation of Aryl Alkyl Ethers
作者:Iain Robb、John A. Murphy
DOI:10.1021/acs.orglett.4c00392
日期:2024.3.22
We report the site-selective α-aryloxyalkyl C–H cyanation and allylation of arylalkylethers using an acridinium photocatalyst with phosphate base under LED irradiation (456 nm). Oxidation of the arylalkylether to its corresponding radical cation by the excited stated photocatalyst allowed facile deprotonation of the ArOC(sp3)–H bond to afford an α-aryloxyalkyl radical, which was trapped with sulfone
Novel amide and amidine derivates and uses thereof
申请人:Abbott Laboratories
公开号:EP2243479A2
公开(公告)日:2010-10-27
The present invention relates to inhibitors of 11- β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.